Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

BHVN has been the subject of several other reports. Morgan Stanley initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, May 31st. They set an “overweight” rating for the company. William Blair initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “outperform” rating and a $46.00 price objective for the company. Barclays PLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “overweight” rating and a $30.00 price objective for the company. Piper Jaffray Companies initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “overweight” rating and a $21.00 price objective for the company. Finally, Needham & Company LLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set a “buy” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Biohaven Pharmaceutical Holding Co presently has an average rating of “Buy” and a consensus target price of $31.75.

Biohaven Pharmaceutical Holding Co (BHVN) traded up 0.40% during midday trading on Friday, reaching $38.12. 86,268 shares of the company traded hands. The stock’s market capitalization is $1.37 billion. Biohaven Pharmaceutical Holding Co has a 12 month low of $17.00 and a 12 month high of $38.56. The firm has a 50 day moving average of $28.89 and a 200-day moving average of $25.68.

ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/08/biohaven-pharmaceutical-holding-co-ltd-bhvn-upgraded-by-zacks-investment-research-to-hold-2.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical Holding Co (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.